Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,893 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Patients Clear all

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 16
States / cities: Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 12 more

Conditions: Prostate Cancer
Interventions: Peptide Vaccine, Poly IC-LC; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer
Interventions: MUC-2-KLH vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Post-Brachytherapy Bladder Outlet Obstruction
Interventions: Memokath 028SW Urethral Stent; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 50 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Degarelix; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 11
States / cities: Homewood, Alabama • Laguna Woods, California • Aventura, Florida + 8 more

Conditions: Prostate Cancer
Interventions: CHESS System, Cancer Information Mentor; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 3
States / cities: Hartford, Connecticut • Houston, Texas • Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: ixabepilone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 28
States / cities: Los Angeles, California • Sacramento, California • Atlanta, Georgia + 19 more

Conditions: Prostate Cancer
Interventions: TAK-700; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Portland, Oregon • Madison, Wisconsin

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Enzalutamide during Lead-in Period, Lead-in Enzalutamide followed by Radium-223/Enzalutamide, Lead-in Enzalutamide followed by Placebo/Enzalutamide, Darolutamide during Lead-in Period, Lead-in Darolutamide followed by Radium-223/Darolutamide, Lead-in Darolutamide followed by Placebo/Darolutamide; Drug
Lead sponsor: MANA RBM; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Myrtle Beach, South Carolina

Conditions: Prostate Cancer
Interventions: tomato-soy juice, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery; Dietary Supplement · Other · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Olaparib, Abiraterone Acetate, Prednisone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Tampa, Florida • Chicago, Illinois + 11 more

Conditions: Metastasis From Malignant Tumor of Prostate (Disorder)
Interventions: 64Cu-PSMA I&T; Drug
Lead sponsor: Curium US LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: New Haven, Connecticut • Hines, Illinois • Baltimore, Maryland + 3 more

Conditions: Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer, Prostate Cancer
Interventions: radiation therapy, stereotactic radiosurgery; Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Modesto, California + 50 more

Conditions: Pain, Prostate Cancer
Interventions: hydromorphone hydrochloride; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer
Interventions: BNT112, Cemiplimab; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Tucson, Arizona • Miami, Florida • Pittsburgh, Pennsylvania + 2 more

Conditions: Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions: placebo, therapeutic conventional surgery, laboratory biomarker analysis, lycopene; Other · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: GI-102, Pasritamig; Drug
Lead sponsor: GI Innovation, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Prostate Cancer
Interventions: Ipatasertib, Abiraterone, Placebo, Prednisone/Prednisolone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 32
States / cities: Chandler, Arizona • Scottsdale, Arizona • Duarte, California + 28 more

Conditions: Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Prostate Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage II Colorectal Cancer AJCC v7, Stage II Prostate Cancer, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer AJCC v7, Stage IIA Prostate Cancer, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer AJCC v7, Stage IIB Prostate Cancer, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7
Interventions: Informational Intervention, Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention; Other · Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 30 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: eRapa (encapsulated rapamycin); Drug
Lead sponsor: Rapamycin Holdings, Inc. dba Emtora Biosciences; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Cancer
Interventions: questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery; Other · Procedure · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Up to 120 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 4
States / cities: Cleveland, Ohio • Westlake, Ohio

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: ESK981; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Detroit, Michigan • Seattle, Washington

Conditions: Prostate Cancer
Interventions: Shared decision-making for PSA screening tool; Behavioral
Lead sponsor: Lisa Richarson; Federal
Eligibility: Not listed
Enrollment: 641 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Prostate Carcinoma
Interventions: Educational Intervention, Electronic Health Record Review, Follow-Up, Internet-Based Intervention, Interview, Survey Administration; Other · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

CHESS: Human and Computer Mentors for Prostate Cancer Patients

BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

Trial of eRapa in Prostate Cancer Patients

Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

Shared Decision Making: Prostate Cancer Screening

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients